A Chinese biotech firm that canceled investor meetings for its Hong Kong initial public offering earlier this month due to the novel coronavirus outbreak is planning to hold them as soon as next week, but likely virtually.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
